Reduce costs with our complimentary sample for evaluation in your lab.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
May 16-20, 2023 Los Angeles, CA Booth #TBC Join the Inotiv team at the American Society of Gene and Cell Therapy’s ...
May 18-21, 2023 St. Louis, MO Booth #6 Come to St. Louis to Be Inspired by New Insights from Leading Experts
May 20-22, 2023 Boston, MA Biomarkers and Precision Oncology World Congress will hold its annual scientific meeting May 20-22, 2023.
WEST LAFAYETTE, Ind., May 25, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research...
WEST LAFAYETTE, Ind., May 19, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug d...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.